Mark McCamish
Direktor/Vorstandsmitglied bei AVADEL PHARMACEUTICALS PLC
Vermögen: 1 Mio $ am 30.04.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Gregory Divis | M | 57 | 7 Jahre | |
| Andrew Dickinson | M | 54 | 4 Jahre | |
| William Conkling | M | 53 | 3 Jahre | |
| Scott House | M | - | 34 Jahre | |
| Jerad G. Seurer | M | - | 7 Jahre | |
| Geoffrey Glass | M | 50 | 6 Jahre | |
| John McLaughlin | M | 72 | 16 Jahre | |
| Joshua Kazam | M | 47 |
IconOVir Bio, Inc.
 IconOVir Bio, Inc. BiotechnologyHealth Technology IconOVir Bio, Inc. is an American biotechnology company that operates in the field of life sciences. The company was founded in 2018 by Arie S. Belldegrun, Ben Stone. The CEO is Mark A. McCamish. | 6 Jahre |
| Arie Belldegrun | M | 74 |
IconOVir Bio, Inc.
IconOVir Bio, Inc. BiotechnologyHealth Technology IconOVir Bio, Inc. is an American biotechnology company that operates in the field of life sciences. The company was founded in 2018 by Arie S. Belldegrun, Ben Stone. The CEO is Mark A. McCamish. | 4 Jahre |
| Ruth Stevens | M | 64 | 3 Jahre | |
| John Lee | M | 56 | 4 Jahre | |
| Scott Leinenweber | M | - | 27 Jahre | |
| Peter Thornton | M | 59 | 7 Jahre | |
| Brett Pletcher | M | 56 | 4 Jahre | |
| Francisco Salva | M | 53 | 4 Jahre | |
| Philip Boudreau | M | 51 | 27 Jahre | |
| Linda Palczuk | F | 62 | 6 Jahre | |
| David Chang | M | 64 |
IconOVir Bio, Inc.
IconOVir Bio, Inc. BiotechnologyHealth Technology IconOVir Bio, Inc. is an American biotechnology company that operates in the field of life sciences. The company was founded in 2018 by Arie S. Belldegrun, Ben Stone. The CEO is Mark A. McCamish. | 4 Jahre |
| Brian Druker | M | 68 | 4 Jahre | |
| David Polinsky | M | 53 | 7 Jahre | |
| Eric Ende | M | 55 | 6 Jahre | |
| Howard Jonas | M | 68 | 7 Jahre | |
| Stephen Greenberg | M | 80 | 6 Jahre | |
| Michael Weiss | M | 73 | 6 Jahre | |
| Laura Bushnell | F | 56 | 4 Jahre | |
| William Kaelin | M | 66 |
IconOVir Bio, Inc.
IconOVir Bio, Inc. BiotechnologyHealth Technology IconOVir Bio, Inc. is an American biotechnology company that operates in the field of life sciences. The company was founded in 2018 by Arie S. Belldegrun, Ben Stone. The CEO is Mark A. McCamish. | 2 Jahre |
| Joyce Mason | F | 65 | 7 Jahre | |
| Amy Johnson | M | - | 3 Jahre | |
| Scott Macke | M | - | 10 Jahre | |
| Melissa Merrick | F | - | 3 Jahre | |
| Gus Kodersha | M | - | 3 Jahre | |
| Denise Strauss | F | - | 3 Jahre | |
| Angela Woods | F | - | 3 Jahre | |
| Daniel E. Morse | M | 82 |
University of California, Santa Barbara
| 51 Jahre |
| Hans-Georg Lerchen | M | - | 3 Jahre | |
| John Goldberg | M | 51 | 1 Jahre | |
| Christina Carlson | F | - | 4 Jahre | |
| Jennifer Gudeman | M | - | 4 Jahre | |
| Jason Vaughn | M | - | 5 Jahre | |
| Helen Kim | F | 61 |
IconOVir Bio, Inc.
IconOVir Bio, Inc. BiotechnologyHealth Technology IconOVir Bio, Inc. is an American biotechnology company that operates in the field of life sciences. The company was founded in 2018 by Arie S. Belldegrun, Ben Stone. The CEO is Mark A. McCamish. | 4 Jahre |
| Brant Schofield | M | - |
Sandoz, Inc.
 Sandoz, Inc. Pharmaceuticals: MajorHealth Technology Sandoz, Inc. develops, manufactures and distributes generic pharmaceutical products. The firm focuses on therapeutic drug categories such as anti-infective, central nervous system disorder treatments, cardiovascular medicines, gastrointestinal agent, oncology therapies, and respiratory therapies. The company was founded in 1946 and is headquartered in Princeton, NJ. | 8 Jahre |
| Peter Goldschmidt | M | 59 |
Sandoz, Inc.
Sandoz, Inc. Pharmaceuticals: MajorHealth Technology Sandoz, Inc. develops, manufactures and distributes generic pharmaceutical products. The firm focuses on therapeutic drug categories such as anti-infective, central nervous system disorder treatments, cardiovascular medicines, gastrointestinal agent, oncology therapies, and respiratory therapies. The company was founded in 1946 and is headquartered in Princeton, NJ. | 11 Jahre |
| Jakob Loven | M | 46 |
IconOVir Bio, Inc.
IconOVir Bio, Inc. BiotechnologyHealth Technology IconOVir Bio, Inc. is an American biotechnology company that operates in the field of life sciences. The company was founded in 2018 by Arie S. Belldegrun, Ben Stone. The CEO is Mark A. McCamish. | - |
| Andrea Wainer | F | - | 27 Jahre | |
| Thomas McHugh | M | 59 | 5 Jahre | |
| Mark Chao | M | - |
IconOVir Bio, Inc.
IconOVir Bio, Inc. BiotechnologyHealth Technology IconOVir Bio, Inc. is an American biotechnology company that operates in the field of life sciences. The company was founded in 2018 by Arie S. Belldegrun, Ben Stone. The CEO is Mark A. McCamish. | 3 Jahre |
| Richard Kim | M | 54 | 3 Jahre | |
| Barbara Ryan | F | 64 | - | |
| Susan Bernstein | F | 59 | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Francis Sarena | M | 53 |
Abbott Biotherapeutics Corp.
 Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 4 Jahre |
| Patrick Fabbio | M | 56 | 2 Jahre | |
| Leonard Patrick Gage | M | 81 | 5 Jahre | |
| Elaine R. Leavenworth | F | 65 | 27 Jahre | |
| Ravindra Majeti | M | 51 | 6 Jahre | |
| Faheem Hasnain | M | 65 | - | |
| Menachem Ash | M | 52 | 4 Jahre | |
| Bradley Margus | M | 63 |
Perlegen Sciences, Inc.
 Perlegen Sciences, Inc. Drugstore ChainsRetail Trade Perlegen Sciences, Inc. discovers and develops drugs. Its product pipeline consists of targeted drug candidates addressing type II diabetes and dyslipidemia markets. The company's products include PGX-510 and PGX-520. It operates in the United States, European Union, and Japan. Perlegen Sciences was co-founded by Brad A. Margus, David R. Cox, and Stephen P. A. Fodor in 2000 and is headquartered in Mountain View, CA | 7 Jahre |
| Shannon Klinger | M | 53 |
Sandoz, Inc.
Sandoz, Inc. Pharmaceuticals: MajorHealth Technology Sandoz, Inc. develops, manufactures and distributes generic pharmaceutical products. The firm focuses on therapeutic drug categories such as anti-infective, central nervous system disorder treatments, cardiovascular medicines, gastrointestinal agent, oncology therapies, and respiratory therapies. The company was founded in 1946 and is headquartered in Princeton, NJ. | 1 Jahre |
| Irving L. Weissman | M | 84 | 6 Jahre | |
| Michael K. Flatten | M | - |
University of California, Santa Barbara
| 6 Jahre |
| Cynthia Shumate | F | 62 | 4 Jahre | |
| Susan Weinschenk | M | - |
The Pennsylvania State University
| 3 Jahre |
| Robert L. Berg | M | - |
The Pennsylvania State University
| 6 Jahre |
| John B. Thomas | M | - | 18 Jahre | |
| Christopher Lowe | M | 56 | 2 Jahre | |
| Herbert Cross | M | 52 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | - |
| Brandi Robinson | F | - | 2 Jahre | |
| Mark R. Ginsberg | M | - |
The Pennsylvania State University
| 4 Jahre |
| David C. Spaulding | M | - |
University of California, Santa Barbara
| 10 Jahre |
| Jim Myers | M | - |
The Pennsylvania State University
| 7 Jahre |
| Kenneth Weirman | M | - |
The Pennsylvania State University
| 6 Jahre |
| Ameet Mallik | M | 51 | 1 Jahre | |
| Paul W. Smith | M | - |
University of California, Santa Barbara
| 5 Jahre |
| Phillandas T. Thompson | M | 50 | 7 Jahre | |
| Boris Pasche | M | 63 | 5 Jahre | |
| Thomas Joseph Dee | M | 60 | 23 Jahre | |
| Michael J. Wyatt | M | - |
The Pennsylvania State University
| 6 Jahre |
| Robert Buly | M | - |
The Pennsylvania State University
| 8 Jahre |
| José Herrero Sáenz de Cabezón | M | 69 |
University of California, Santa Barbara
| 6 Jahre |
| Kristine Ball | M | 52 | 2 Jahre | |
| Richard Murray | M | 65 | 5 Jahre | |
| David A. L. Owen | M | 85 | - | |
| Ian Clark | M | 62 | 2 Jahre | |
| Duane L. Burnham | M | 82 | 9 Jahre | |
| Jeff Bird | M | 63 | 5 Jahre | |
| Dennis J. Henner | M | 72 | 5 Jahre | |
| Jon Saxe | M | 88 | 19 Jahre | |
| Chris Schaepe | M | 61 | 4 Jahre | |
| Mark McDade | M | 69 | 5 Jahre | |
| Paul W. Sandman | M | 76 | 12 Jahre | |
| Andrew Guggenhime | M | 55 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 4 Jahre |
| Steven M. Rauscher | M | 70 | 18 Jahre | |
| Andrew McDonald | M | 50 | 2 Jahre | |
| Jaisim Shah | M | 63 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 9 Jahre |
| Olutoyin Adebola Phillips | M | - |
The Pennsylvania State University
| 3 Jahre |
| J. Scovill | M | 64 |
The Pennsylvania State University
| 4 Jahre |
| Lee Burkett | M | 67 |
The Pennsylvania State University
| 4 Jahre |
| Edward J. Pryts | M | 63 |
The Pennsylvania State University
| 4 Jahre |
| Frank T. Guadagnino | M | - |
The Pennsylvania State University
| 4 Jahre |
| Lou Stanasolovich | M | - |
The Pennsylvania State University
| 4 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 86 | 86,00% |
| Irland | 15 | 15,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Mark McCamish
- Persönliches Netzwerk
